Trial · NCT00585611
Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients
NCT00585611, Not applicable, Terminated, University of Wisconsin, Madison; results first posted 2019-03-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients. Trials, record NCT00585611. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00585611
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients
- NCT number
- NCT00585611
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 1 participants, actual
- Lead sponsor
- University of Wisconsin, Madison
- Conditions
- Diastolic Heart Failure
- Interventions
- Atorvastatin, placebo
- First posted
- 2008-01-03
- Last updated
- 2019-03-26
- Results first posted
- 2019-03-26
- Limitations and caveats
- PI left UW-Madison, has no data for participant enrolled.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Carotid-femoral Pulse Wave Velocity (CFPWV) in the Statin Treated vs. Control Group | 6 months after initiation of intervention | |
| Secondary | Composite Cardiovascular Endpoint Incorporating Quality of Life (QOL) Assessment + Hospitalizations for Cardiovascular Disease and Mortality | 6 months after initiation of intervention | |
| Secondary | Changes in Submaximal Exercise Capacity Measured by 6-minute Walk Test | 6 months after initiation of intervention |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Carotid-femoral Pulse Wave Velocity (CFPWV) in the Statin Treated vs. Control Group | 6 months after initiation of intervention | There are no data available | ||
| SECONDARY | Composite Cardiovascular Endpoint Incorporating Quality of Life (QOL) Assessment + Hospitalizations for Cardiovascular Disease and Mortality | 6 months after initiation of intervention | There are no data available. | ||
| SECONDARY | Changes in Submaximal Exercise Capacity Measured by 6-minute Walk Test | 6 months after initiation of intervention | There are no data available. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Atorvastatin | 0 | |
| Overall Study | STARTED | Arm 2 | 0 | |
| Overall Study | COMPLETED | Atorvastatin | 0 | |
| Overall Study | COMPLETED | Arm 2 | 0 | |
| Overall Study | NOT COMPLETED | Atorvastatin | 0 | |
| Overall Study | NOT COMPLETED | Arm 2 | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Atorvastatin | 0 | 0 |
| Total, all-cause mortality | Arm 2 | 0 | 0 |
| Total, other adverse events | Atorvastatin | 0 | 0 |
| Total, other adverse events | Arm 2 | 0 | 0 |
| Total, serious adverse events | Atorvastatin | 0 | 0 |
| Total, serious adverse events | Arm 2 | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00585611
GET https://conductscience.org/api/trials/v1/NCT00585611/registered